{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Lung+Non-Small+Cell+Carcinoma", "query": { "condition": "Locally Advanced Lung Non-Small Cell Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 393, "total_pages": 40, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Lung+Non-Small+Cell+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-21T22:32:19.830Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00312377", "title": "ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Vandetanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1690, "start_date": "2006-05", "completion_date": "2014-03", "has_results": true, "last_update_posted_date": "2016-09-30", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 27, "location_summary": "Fullerton, California • Los Angeles, California • Northridge, California + 24 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00312377" }, { "nct_id": "NCT02122146", "title": "A Study Of PF-06664178 In Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PF-06664178", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2014-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2018-02-19", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 10, "location_summary": "Los Angeles, California • Aurora, Colorado • Seattle, Washington", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02122146" }, { "nct_id": "NCT06875310", "title": "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Adagrasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-04-24", "completion_date": "2032-04-30", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06875310" }, { "nct_id": "NCT04895579", "title": "Lung Cancer With Copanlisib and Durvalumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Copanlisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zhonglin Hao", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2021-05-12", "completion_date": "2025-11-12", "has_results": false, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895579" }, { "nct_id": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Alectinib", "type": "DRUG" }, { "name": "Entrectinib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2022-11-01", "completion_date": "2030-06-16", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 2, "location_summary": "Tigard, Oregon • Pittsburgh, Pennsylvania", "locations": [ { "city": "Tigard", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05170204" }, { "nct_id": "NCT02544633", "title": "Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "MGCD265", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirati Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2015-10", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02544633" }, { "nct_id": "NCT04680377", "title": "Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "NSCLC, Stage III", "Locally Advanced Lung Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Jun Zhang, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2021-04-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 2, "location_summary": "Kansas City, Kansas • Providence, Rhode Island", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT04680377" }, { "nct_id": "NCT03481114", "title": "Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "PET-based, dose-painted, accelerated chemoradiotherapy", "type": "COMBINATION_PRODUCT" }, { "name": "Standard chemoradiotherapy", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Albert Einstein College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2017-08-28", "completion_date": "2023-12-27", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03481114" }, { "nct_id": "NCT04746924", "title": "A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 669, "start_date": "2021-05-24", "completion_date": "2026-03-18", "has_results": true, "last_update_posted_date": "2026-05-12", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Ocala, Florida + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04746924" }, { "nct_id": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "NSCLC", "Non Small Cell Lung Cancer", "NSCLC, Recurrent", "Non-Small Cell Squamous Lung Cancer", "Pancreas Cancer", "Pancreatic Neoplasm", "Colorectal Adenocarcinoma", "CRC", "Colon Cancer", "Rectal Cancer", "Cancer", "Ovarian Cancer", "Ovarian Neoplasms", "Mesothelioma", "Mesothelioma, Malignant", "Ovary Cancer", "Lung Cancer", "MESOM" ], "interventions": [ { "name": "A2B694", "type": "BIOLOGICAL" }, { "name": "A2B543", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH Assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 474, "start_date": "2024-04-03", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-21T22:32:19.830Z", "location_count": 12, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 9 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06051695" } ] }